The global head and neck cancer therapeutics market size was valued at USD 2.5 billion in 2025 and is projected to grow from USD 2.8 billion in 2026 to USD 6.3 billion by 2033, at a CAGR of 12.0% from 2026 to 2033. The market in North America dominated with a revenue share of 44.6% in 2025. The market is growing due to the rising incidence of head and neck cancers, increasing demand for targeted and immunotherapy-based treatments, and advancements in diagnostic precision.
read more..